Hypertrophic cardiomyopathy
Conditions
Brief summary
A test of the null hypothesis that the mean VO 2 max measured 12 months after randomization is the same in the treatment group and the placebo group;, A null hypothesis test that the mean KCCQ-OS value measured 12 months after randomization is the same in the treatment group and the placebo group.
Detailed description
The secondary objective of the trial is to test the null hypothesis that the mean value of the VO 2 max measured 12 months after randomization is the same in the treatment group treated group and the placebo group among patients with reduced left ejection fraction ventricle.
Interventions
DRUGMicrocrystalline cellulose
DRUGmagnesium stearate
DRUGJardiance 10 mg film-coated tablets
Sponsors
Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A test of the null hypothesis that the mean VO 2 max measured 12 months after randomization is the same in the treatment group and the placebo group;, A null hypothesis test that the mean KCCQ-OS value measured 12 months after randomization is the same in the treatment group and the placebo group. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objective of the trial is to test the null hypothesis that the mean value of the VO 2 max measured 12 months after randomization is the same in the treatment group treated group and the placebo group among patients with reduced left ejection fraction ventricle. | — |
Countries
Poland
Outcome results
None listed